clinical trial · NCT03260894
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Renal Cell Carcinoma (RCC)PembrolizumabEpacadostatSunitinibPazopanib
brief summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
started
Dec 7, 2017
primary completion
Aug 22, 2018
completion
Jun 4, 2025
last updated
Jul 29, 2025
official title
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol